目的 評估二甲雙胍治療2型糖尿病患者罹患肝癌的風(fēng)險。方法 從PubMed、Embase、中國期刊全文數(shù)據(jù)庫（CNKI）、維普全文數(shù)據(jù)庫（VIP）萬方等數(shù)據(jù)庫獲得關(guān)于二甲雙胍與糖尿病患者罹患肝癌風(fēng)險的相關(guān)研究，評價二甲雙胍治療糖尿病過程中，患者罹患肝癌的風(fēng)險，檢索時限為從建庫至2017年12月。結(jié)果 共納入11篇相關(guān)文獻，其中病例對照研究8篇，隊列研究3篇；共計123 412例患者，其中實驗組78 817例，對照組44 595例。病例對照研究Meta-分析結(jié)果顯示，與其他降糖藥相比，二甲雙胍治療可使2型糖尿病患者肝癌發(fā)病風(fēng)險降低42%［RR=0.58，95% CI（0.52，0.65），P=0.000 01］；隊列研究Meta-分析結(jié)果則顯示，二甲雙胍治療可使2型糖尿病患者肝癌發(fā)病風(fēng)險降低47%［RR=0.53，95% CI（0.13，2.21），P=0.38］。結(jié)論 二甲雙胍治療可降低2型糖尿病患者罹患肝癌的風(fēng)險。

Objective To evaluate the risk of morbidity of liver cancer in type 2 diabetes treated with metformin. Methods The cohort studies and case-control studies in evaluating the effect of metformin on liver cancer in type 2 diabetes were researched from PubMed, Embase, CNKI, VIP and Wanfang Data until December 2016. Results A total of 11 articles were included, eight of which were case-control studies and three were cohort studies. A total of 123 412 patients, including 78 817 patients in the experimental group and 44 595 cases in the control group. Meta-analysis of case-control studies showed that metformin treatment can reduce the risk of morbidity of liver cancer in type 2 diabetes by 42%[RR=0.58, 95%CI(0.52, 0.65), P=0.000 01] compared with other antidiabetic drugs; the results from the cohort studies showed that metformin therapy can reduce the risk of morbidity of liver cancer in type 2 diabetes patients by 47%[RR=0.53, 95%CI(0.13, 2.21), P=0.38] compared with those with other antidiabetic drugs. Conclusion Metformin therapy can reduce the risk of morbidity of liver cancer in patients with type 2 diabetes.

四川省教育廳重點項目（16ZA0178）；瀘州市科技局項目［2016-R-70（11/24）］